Xencor (NASDAQ:XNCR – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Truist Financial in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $29.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $27.00. Truist Financial’s target price indicates […]